Yew Bio-Pharm Group, Inc. (YEWB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Yew Bio-Pharm Group, Inc. (YEWB) trades at $0.00 with AI Score 38/100 (Grade D). Yew Bio-Pharm Group, Inc. cultivates and sells yew trees, offering raw materials for traditional Chinese medicine (TCM). Market cap: $11,838, Sector: Consumer defensive.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for YEWB: YEWB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates YEWB against Consumer Defensive peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
YEWB: 1/1 perspectives are bearish.
How is this calculated? →Yew Bio-Pharm Group, Inc. (YEWB) Consumer Business Overview
Yew Bio-Pharm Group, Inc. focuses on the cultivation and sale of yew trees, providing raw materials for traditional Chinese medicine and producing various yew-derived products. Operating in the consumer defensive sector, the company caters to both TCM markets and niche consumer segments with its diverse product offerings in China and the United States.
What Is the Investment Thesis for YEWB?
Yew Bio-Pharm Group, Inc. presents a unique investment opportunity within the agricultural farm products sector, leveraging the growing demand for traditional Chinese medicine (TCM) and niche consumer products. With a market capitalization of 12K and a P/E ratio of 0.0, the company demonstrates potential for value creation. A key value driver is the company's 5.4% profit margin and 12.9% gross margin, indicating efficient operations. Growth catalysts include expanding its product line of yew-derived products and penetrating new markets in the TCM and consumer sectors. Potential risks include competition from larger agricultural companies and fluctuations in demand for TCM raw materials. Investors should monitor the company's ability to scale its operations and maintain profitability in a competitive landscape.
Based on FMP financials and quantitative analysis
YEWB Key Highlights
- Market Cap of 12K reflects the company's small size and potential for growth.
- P/E Ratio of 0.0 indicates that the company may be undervalued relative to its earnings.
- Profit Margin of 5.4% demonstrates the company's ability to generate profit from its revenue.
- Gross Margin of 12.9% shows the percentage of revenue remaining after deducting the cost of goods sold.
- Beta of -0.68 suggests that the stock is less volatile than the market, potentially offering stability in turbulent times.
Who Are YEWB's Competitors?
YEWB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FSRCY First Resources Limited | $238.46 | +0.00% | $3.69B | 64 |
| FTROF First Resources Limited | $1.80 | -20.35% | $2.79B | 64 |
| CALM Cal-Maine Foods, Inc. | $83.98 | +0.16% | $3.98B | 64 |
| UOLI Uonlive Corporation | $5.75 | +0.00% | 63 | |
| WLMIF Wilmar International Limited | $2.78 | +0.00% | $17.36B | 46 |
| TSN Tyson Foods, Inc. | $58.63 | -0.44% | $20.87B | 47 |
| ORENF Origin Enterprises plc | $4.86 | +0.00% | $522.39M | 48 |
| AGRO Adecoagro S.A. | $9.51 | -1.35% | $5.37B | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are YEWB's Key Strengths?
- Specialized expertise in yew tree cultivation and processing.
- Diversified product line of yew-based products.
- Geographic presence in both China and the United States.
- Established relationships with TCM manufacturers.
What Are YEWB's Weaknesses?
- Small market capitalization and limited financial resources.
- Dependence on the demand for TCM raw materials.
- Limited brand recognition and marketing capabilities.
- Vulnerability to fluctuations in agricultural commodity prices.
What Could Drive YEWB Stock Higher?
- Expansion of TCM raw material supply to meet growing global demand.
- Diversification of yew-based product line to attract new customers.
- Penetration of new geographic markets in the TCM and consumer sectors.
- Enhancement of e-commerce presence to increase sales and market reach.
- Strategic partnerships and collaborations with TCM manufacturers and retailers.
What Are the Key Risks for YEWB?
- Financial-distress signal — its Altman Z-Score of 1.26 sits in the distress zone (elevated bankruptcy risk).
- Competition from larger agricultural companies and TCM suppliers.
- Changes in government regulations affecting TCM and agricultural practices.
- Fluctuations in demand for TCM raw materials due to changing consumer preferences.
- Environmental risks affecting yew tree cultivation.
- Limited financial resources and small market capitalization.
What Are the Growth Opportunities for YEWB?
- Expanding TCM Raw Material Supply: The increasing global interest in traditional Chinese medicine (TCM) presents a significant growth opportunity for Yew Bio-Pharm Group. The company can capitalize on this trend by expanding its yew tree cultivation and processing capabilities to meet the rising demand for TCM raw materials. The global TCM market is projected to reach $400 billion by 2027, offering a substantial market for Yew Bio-Pharm to penetrate further. Timeline: Ongoing.
- Diversifying Yew-Based Product Line: Yew Bio-Pharm Group can drive growth by diversifying its product line of yew-based products, including furniture, handicrafts, cosmetics, and agricultural products. By introducing innovative and high-quality products, the company can attract new customers and increase its market share. The global cosmetics market is expected to reach $800 billion by 2028, providing a large market for Yew Bio-Pharm to tap into. Timeline: Ongoing.
- Penetrating New Geographic Markets: Yew Bio-Pharm Group can expand its geographic reach by penetrating new markets in the TCM and consumer sectors. The company can target regions with a high demand for TCM products and a growing interest in natural and sustainable products. Asia-Pacific is a key market for TCM, with a market size of over $100 billion. Timeline: Ongoing.
- Enhancing E-Commerce Presence: Strengthening its online presence through e-commerce platforms can significantly boost Yew Bio-Pharm Group's sales and market reach. By developing a user-friendly online store and implementing effective digital marketing strategies, the company can attract a wider customer base and increase its brand visibility. The global e-commerce market is projected to reach $6 trillion by 2024, offering a substantial opportunity for Yew Bio-Pharm to leverage. Timeline: Upcoming: 2027.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with TCM manufacturers, retailers, and research institutions can accelerate Yew Bio-Pharm Group's growth. By collaborating with established players in the industry, the company can gain access to new markets, technologies, and expertise. Strategic alliances can enhance Yew Bio-Pharm's competitive advantage and drive innovation. Timeline: Upcoming: 2027.
What Opportunities Does YEWB Have?
- Expanding TCM raw material supply to meet growing global demand.
- Diversifying yew-based product line to attract new customers.
- Penetrating new geographic markets in the TCM and consumer sectors.
- Enhancing e-commerce presence to increase sales and market reach.
What Threats Does YEWB Face?
- Competition from larger agricultural companies and TCM suppliers.
- Changes in government regulations affecting TCM and agricultural practices.
- Fluctuations in demand for TCM raw materials due to changing consumer preferences.
- Potential environmental risks affecting yew tree cultivation.
What Are YEWB's Competitive Advantages?
- Specialized Expertise: Deep understanding of yew tree cultivation and processing for TCM applications.
- Product Diversification: Wide range of yew-based products, including raw materials, furniture, and cosmetics.
- Geographic Presence: Operations in both China and the United States, providing access to key markets.
- Established Relationships: Strong relationships with TCM manufacturers and retailers.
What Does YEWB Do?
Incorporated in 2007 and based in El Monte, California, Yew Bio-Pharm Group, Inc. cultivates and sells yew trees through its subsidiaries in the People's Republic of China and the United States. The company's primary focus is supplying traditional Chinese medicine (TCM) manufacturers with yew tree branches and leaves, essential raw materials for producing TCM containing taxol. Beyond raw materials, Yew Bio-Pharm Group engages in processing and selling yew raw materials for TCM, growing and selling yew tree seedlings and mature trees, including potted miniature yew trees. Diversifying its product line, the company manufactures and sells furniture and handicrafts made from yew tree timber. Additionally, Yew Bio-Pharm Group offers agricultural products such as yew candles, pine needle extracts, taxus cuspidate extracts, northeast yew extracts, and yew essential oil soaps. The company also markets and sells cosmetics and wood ear mushrooms, expanding its reach within the consumer market. Yew Bio-Pharm Group operates within the consumer defensive sector, targeting niche markets with its specialized yew-based products.
What Products and Services Does YEWB Offer?
- Cultivates and sells yew trees in China and the United States.
- Supplies yew tree branches and leaves as raw materials for traditional Chinese medicine (TCM).
- Processes and sells yew raw materials used in the manufacture of TCM.
- Grows and sells yew tree seedlings and mature trees, including potted miniature yew trees.
- Manufactures and sells furniture and handicrafts made of yew tree timber.
- Sells agricultural products, such as yew candles, pine needle extracts, and yew essential oil soaps.
- Markets and sells cosmetics.
How Does YEWB Make Money?
- Generates revenue from the sale of yew trees and yew tree seedlings.
- Earns income from processing and selling yew raw materials to TCM manufacturers.
- Derives revenue from the sale of yew-based products, including furniture, handicrafts, and cosmetics.
- Expands market reach through e-commerce and strategic partnerships.
What Industry Does YEWB Operate In?
Yew Bio-Pharm Group, Inc. operates within the agricultural farm products industry, a segment of the broader consumer defensive sector. The industry is characterized by stable demand, as agricultural products are essential goods. The market for traditional Chinese medicine (TCM) raw materials is growing, driven by increasing consumer interest in natural remedies. Competition includes both large agricultural companies and smaller niche players. Yew Bio-Pharm Group differentiates itself by specializing in yew tree cultivation and offering a diverse range of yew-based products. The company's success depends on its ability to efficiently manage its supply chain, maintain product quality, and adapt to changing consumer preferences.
Who Are YEWB's Key Customers?
- Traditional Chinese medicine (TCM) manufacturers who use yew tree extracts in their products.
- Retail consumers who purchase yew-based furniture, handicrafts, and cosmetics.
- Nurseries and landscaping companies that buy yew tree seedlings and mature trees.
- Online customers who purchase products through the company's e-commerce platform.
F-Score 6/9Financial Health
Yew Bio-Pharm Group, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.26 places it in the distress zone, a signal of elevated financial risk.
YEWB Valuation & Market Position
With a 12K market cap, Yew Bio-Pharm Group, Inc. sits in the micro-cap segment of the market. Relative to its peer group, YEWB's quantitative score of 38/100 is below the peer average of 60/100.
ROE 3%Key Financial Metrics
Return on equity for Yew Bio-Pharm Group, Inc. stands at 3.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.5%, showing how much profit it generates from its asset base. YEWB trades at a trailing price-to-earnings ratio of 0.01, below the Consumer Defensive sector average of ~29x. A current ratio of 0.95 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Yew Bio-Pharm Group, Inc. operates in the Agricultural Farm Products industry within the Consumer Defensive sector. It is headquartered in El Monte, US. The company is led by CEO Madam Guifang Qi. YEWB has traded publicly since 2013.
YEWB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting Yew Bio-Pharm's innovative approach to natural health products.
- The market is increasingly focused on sustainability, and Yew's commitment to eco-friendly practices resonates with socially conscious investors.
- Recent partnerships in the health sector have raised the company's profile, attracting attention from both consumers and industry experts.
Bear Case
- Some analysts express concerns about the competitive landscape, noting that the natural health market is becoming saturated with new entrants.
- Recent social sentiment has shown skepticism regarding the company's ability to scale operations effectively in a rapidly changing market.
- There are whispers of potential regulatory challenges that could hinder Yew's growth trajectory, creating uncertainty among investors.
- The overall market sentiment towards biotech firms has been cautious, with many investors wary of volatility in the sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
YEWB Latest News
No recent news available for YEWB.
YEWB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for YEWB.
Price Targets
Wall Street price target analysis for YEWB.
YEWB MoonshotScore
What does this score mean?
The MoonshotScore rates YEWB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Agricultural Farm ProductsLeadership: Madam Guifang Qi
CEO
Madam Guifang Qi serves as the CEO of Yew Bio-Pharm Group, Inc. Her leadership is pivotal in guiding the company's strategic direction and operational execution. She oversees the cultivation, processing, and sale of yew trees and related products in both China and the United States. Madam Qi's background includes extensive experience in agricultural management and international trade, providing her with a strong foundation for leading Yew Bio-Pharm Group.
Track Record: Under Madam Qi's leadership, Yew Bio-Pharm Group has expanded its product line and strengthened its relationships with TCM manufacturers. She has focused on improving operational efficiency and penetrating new markets. Her strategic decisions have contributed to the company's growth and profitability. She manages 35 employees.
YEWB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Yew Bio-Pharm Group, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: OTC companies may have limited financial reporting requirements, making it difficult to assess their financial health.
- Low Liquidity: OTC stocks often have low trading volumes, leading to wider bid-ask spreads and potential price volatility.
- Regulatory Scrutiny: OTC companies may not be subject to the same level of regulatory oversight as companies listed on major exchanges.
- Information Asymmetry: Investors may have limited access to information about OTC companies, increasing the risk of making uninformed decisions.
- Potential for Fraud: The OTC market is more susceptible to fraud and manipulation due to the lack of regulatory oversight.
- Verify the company's registration and legal status.
- Review the company's financials, if available.
- Assess the company's management team and their experience.
- Research the company's industry and competitive landscape.
- Understand the company's business model and revenue streams.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a financial advisor before investing.
- Established Operations: Yew Bio-Pharm Group has been in operation since 2007, indicating a degree of stability.
- Tangible Assets: The company cultivates and sells yew trees, representing tangible assets.
- Diverse Product Line: The company offers a range of yew-based products, suggesting a diversified revenue stream.
- International Presence: The company operates in both China and the United States, indicating a broader market reach.
What Investors Ask About Yew Bio-Pharm Group, Inc. (YEWB) — Consumer Defensive
What does Yew Bio-Pharm Group, Inc. do?
Yew Bio-Pharm Group, Inc. specializes in the cultivation, processing, and sale of yew trees and related products. The company supplies yew tree branches and leaves as raw materials for traditional Chinese medicine (TCM) manufacturers. Additionally, Yew Bio-Pharm Group produces and markets a range of yew-based products, including furniture, handicrafts, cosmetics, and agricultural products. The company operates in both China and the United States, targeting the growing demand for TCM and niche consumer markets with its diverse product offerings.
What are the main risks for YEWB?
Yew Bio-Pharm Group, Inc. faces several risks, including competition from larger agricultural companies and TCM suppliers. Changes in government regulations affecting TCM and agricultural practices could also impact the company's operations. Fluctuations in demand for TCM raw materials due to changing consumer preferences pose a risk to revenue. Additionally, environmental risks affecting yew tree cultivation could disrupt the company's supply chain. As an OTC-listed company, YEWB is subject to lower liquidity and greater price volatility.
How does Yew Bio-Pharm Group, Inc. adapt to changing consumer preferences?
Yew Bio-Pharm Group, Inc. adapts to changing consumer preferences by continuously innovating its product line and expanding its market reach. The company monitors consumer trends in the TCM and consumer sectors to identify new product opportunities. Yew Bio-Pharm Group also leverages e-commerce platforms and digital marketing strategies to reach a wider customer base and promote its products. By diversifying its product offerings and enhancing its online presence, the company aims to cater to evolving consumer demands and maintain its competitive edge.
How does Yew Bio-Pharm Group, Inc. manage supply chain and input cost risks?
Yew Bio-Pharm Group, Inc. manages supply chain and input cost risks by maintaining a diversified network of suppliers and implementing efficient inventory management practices. The company also invests in research and development to improve yew tree cultivation techniques and reduce production costs. Yew Bio-Pharm Group closely monitors agricultural commodity prices and market trends to anticipate potential fluctuations and adjust its pricing strategies accordingly. By optimizing its supply chain and controlling input costs, the company aims to mitigate risks and maintain profitability.
What are the key factors to evaluate for YEWB?
Yew Bio-Pharm Group, Inc. (YEWB) holds an AI score of 38/100 (low). P/E: 0.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does YEWB data refresh on this page?
YEWB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven YEWB's recent stock price performance?
Yew Bio-Pharm Group, Inc. (YEWB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in yew tree cultivation and processing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider YEWB overvalued or undervalued right now?
Yew Bio-Pharm Group, Inc. (YEWB) trades at 0.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be limited.
- OTC market investments carry higher risks due to limited regulation and disclosure.